


RESEARCH

Open Access



# ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells

Madhobi Sen<sup>1</sup>, Xin Wang<sup>1</sup>, Feda H. Hamdan<sup>2</sup>, Jacobe Rapp<sup>1</sup>, Jessica Eggert<sup>1</sup>, Robyn Laura Kosinsky<sup>1</sup>, Florian Wegwitz<sup>1</sup>, Ana Patricia Kutschat<sup>1</sup>, Fereshteh S. Younesi<sup>1</sup>, Jochen Gaedcke<sup>1</sup>, Marian Grade<sup>1</sup>, Elisabeth Hessmann<sup>3</sup>, Argyris Papanonis<sup>4</sup>, Philipp Ströbel<sup>4</sup> and Steven A. Johnsen<sup>2\*</sup> 

## Abstract

**Background:** ARID1A (AT-rich interactive domain-containing protein 1A) is a subunit of the BAF chromatin remodeling complex and plays roles in transcriptional regulation and DNA damage response. Mutations in *ARID1A* that lead to inactivation or loss of expression are frequent and widespread across many cancer types including colorectal cancer (CRC). A tumor suppressor role of ARID1A has been established in a number of tumor types including CRC where the genetic inactivation of *Arid1a* alone led to the formation of invasive colorectal adenocarcinomas in mice. Mechanistically, ARID1A has been described to largely function through the regulation of enhancer activity.

**Methods:** To mimic ARID1A-deficient colorectal cancer, we used CRISPR/Cas9-mediated gene editing to inactivate the *ARID1A* gene in established colorectal cancer cell lines. We integrated gene expression analyses with genome-wide ARID1A occupancy and epigenomic mapping data to decipher ARID1A-dependent transcriptional regulatory mechanisms.

**Results:** Interestingly, we found that CRC cell lines harboring *KRAS* mutations are critically dependent on ARID1A function. In the absence of ARID1A, proliferation of these cell lines is severely impaired, suggesting an essential role for ARID1A in this context. Mechanistically, we showed that ARID1A acts as a co-factor at enhancers occupied by AP1 transcription factors acting downstream of the MEK/ERK pathway. Consistently, loss of *ARID1A* led to a disruption of KRAS/AP1-dependent enhancer activity, accompanied by a downregulation of expression of the associated target genes.

**Conclusions:** We identify a previously unknown context-dependent tumor-supporting function of ARID1A in CRC downstream of KRAS signaling. Upon the loss of ARID1A in *KRAS*-mutated cells, enhancers that are co-occupied by ARID1A and the AP1 transcription factors become inactive, thereby leading to decreased target gene expression. Thus, targeting of the BAF complex in *KRAS*-mutated CRC may offer a unique, previously unknown, context-dependent therapeutic option in CRC.

**Keywords:** ARID1A, BAF complex, *KRAS*, MEK/ERK pathway, AP1, Enhancers, Transcriptional regulation, Colorectal cancer

\* Correspondence: [Johnsen.Steven@mayo.edu](mailto:Johnsen.Steven@mayo.edu)

<sup>2</sup>Gene Regulatory Mechanisms and Molecular Epigenetics Lab, Gastroenterology Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

## Background

In 2018, colorectal cancer (CRC) was estimated to be the third most commonly occurring cancer and the second leading cause of cancer-related deaths [1]. An accumulation of mutations in several key pathways occurs during the transformation from normal colonic epithelium to a malignant carcinoma [2]. Genes involved in these pathways such as *APC*, *KRAS*, and *TP53* represent a large fraction of the mutations prevalent in CRC. Notably, the *KRAS* oncogene is mutated in approximately 30% of CRC cases (cBioPortal for Cancer Genomics) [3, 4]. These mutations generally lead to increased proliferation and survival via downstream activation of signaling through the Raf/MEK/ERK cascade [5]. *KRAS* signaling ultimately relays information to the intracellular transcriptional machinery via AP1 transcription factors, which dimerize and bind to the DNA upon phosphorylation, where they recruit further transcriptional regulators to modulate gene expression [6, 7].

Followed by mutation of well-known tumor suppressor and oncogenes such as those listed above, the *ARID1A* gene is among the most frequently mutated genes in human CRC, where it is mutated in 10.9% of cases (TCGA PanCancer Atlas dataset, cBioPortal for Cancer Genomics) [3, 4]. Interestingly, this frequency is even higher than mutational rates of several other bona fide tumor suppressor genes such as *PTEN* (6.4%) (cBioportal for Cancer Genomics) [3, 4]. *ARID1A* is a subunit of the human BAF (BRG1-associated factors) complex [8, 9], which is primarily involved in chromatin remodeling. Chromatin remodelers such as the BAF complex are large, multi-subunit complexes that utilize the energy of ATP hydrolysis to mobilize, slide, and evict nucleosomes [10, 11]. In vitro, four core subunits are required to dissociate nucleosomes from the DNA on a chromatin template. These include the mutually exclusive ATPases SMARCA2 or SMARCA4 (BRG1) and core subunits SMARCB1, SMARCC1, and SMARCC2 that enhance catalytic activity [12]. The exact role of the other BAF subunits is not very well understood, but mutation rates in cancer suggest important roles in vivo. As a regulator of chromatin structure and function, the BAF complex plays crucial roles in transcription and epigenetic modulation of gene expression [13–17].

The deregulation of epigenetic modulation has been well established as a common occurrence in cancer. However, the extent of its involvement in the development and progression of cancer was underscored by genome- and exome-wide sequencing studies which revealed a close association between the epigenome and the pathogenesis of cancer. Most significantly, subunits of the mammalian BAF complex show an alteration frequency in over 20% of all cancers [18, 19]. Among BAF complex subunits, *ARID1A* mutations are the most recurrent and widespread across many cancer types [18]. These mutations often lead to a loss of *ARID1A* expression in tumors, and *ARID1A*


has been extensively described as a tumor suppressor in the literature [20–25]. Consistently, the sporadic deletion of *Arid1a* in mice led to the formation of invasive adenocarcinomas in the colon [21].

While the BAF complex has also been shown to play a role in DNA damage repair [26], its primary role appears to be in enhancer-mediated gene regulation [21, 27–32]. Enhancers are transcriptionally active, distal regulatory elements which modulate the expression of their target genes [33]. While initial studies reported that *ARID1A* occupied promoter regions [34, 35], several studies have since shown that the BAF complex is targeted to enhancers [21, 27–32]. In fact, the tumor suppressive functions of the BAF complex have been suggested to be primarily through its function in controlling enhancer-mediated gene regulation [21, 27, 29]. In colorectal cancer, it was shown that the activity of BAF-occupied enhancers is reduced in *ARID1A*-deficient cells and accompanied by a loss of the active H3K27ac mark (acetylation of lysine 27 on histone 3) [21]. In this study, we sought to examine the transcriptional mechanisms underlying the tumor suppressor function of *ARID1A* in colorectal cancer. Surprisingly, we uncovered a previously unknown context-dependent function of *ARID1A* in promoting AP1 transcription factor activity downstream of *KRAS* signaling.

## Results

### *ARID1A* protein loss is a frequent event in colorectal cancer

To begin with, we examined the mutation frequency for *ARID1A* in colorectal cancer patients. Analysis of several large datasets revealed an alteration frequency of up to ~12% (cBioPortal for Cancer Genomics) [3, 4] (Fig. 1a). Since mutations in *ARID1A* have been shown to lead to the loss of protein expression in tumors [25, 36–38], we next examined the frequency of the loss of *ARID1A* protein expression by immunohistochemical analysis of tissue microarrays from treatment naïve rectal cancer patients. As shown in the representative images in Fig. 1b, the immunohistochemical staining for *ARID1A* was specific with normal rectal mucosa demonstrating positive *ARID1A* staining, whereas tumors were either strongly positive (++), weakly positive (+), or negative for *ARID1A* expression (negative). Overall, out of 164 patients, 81.7% retained *ARID1A* expression in their tumors (Fig. 1c). Consistent with the mutation rates, we observed a complete loss of *ARID1A* protein expression in 14.6% of the cases (Fig. 1c) and 3.7% of patient tumors showed a weak staining pattern (Fig. 1c). The weak positivity could perhaps be attributed to a heterozygous loss of *ARID1A*. These findings demonstrate that the loss of *ARID1A* protein expression is a frequent occurrence in rectal cancer patients.



**Fig. 1** *ARID1A* protein loss in human cancer samples is consistent with mutation rates. *ARID1A* is mutated in up to ~12% colorectal cancers from different colorectal cancer cohorts [3, 4] (a). Representative immunohistochemical staining images show clear *ARID1A* staining in the rectal mucosa and positive tumors while negative tumors show no staining at all (b). The University Medical Center Göttingen rectal cancer cohort showed 81.7% strongly positive *ARID1A* staining (++) and 3.7% showed weakly positive staining (+) while 14.6% of the samples were negative for *ARID1A* staining (c)

### The loss of *ARID1A* leads to impaired proliferation in a subset of colorectal cancer cell lines


Given its pivotal tumor suppressive role in vivo, we next sought to explore the consequences of *ARID1A* loss at the molecular level in an in vitro system. For this purpose, we utilized a CRISPR/Cas9-mediated gene editing approach to delete a portion of the *ARID1A* gene in four colorectal cancer cell lines (COLO320DM, DLD1, HCT116, and HT29). These cell lines were specifically chosen because they expressed several BAF complex subunits to varying degrees (Additional file 1: Figure S1a) and also represent a varied mutational background representative of the diversity found in human CRC tumors. For example, HCT116 and DLD1 both contain *KRAS*<sup>G13D</sup> mutations, whereas COLO320DM and HT29 are wild type for this gene. Similarly, all cell lines except HCT116 harbor mutations in *TP53* (cBioPortal for Cancer Genomics) [3, 4]. The guide RNAs utilized specifically target two intronic regions flanking exon 5 of *ARID1A*, resulting in a frameshift of any potentially transcribed and spliced product from the mutant allele (Fig. 2a). We screened single cell clones of each cell line for deletion (KO) of *ARID1A* by genotyping PCR (Fig. 2a) and Western blot for protein (Fig. 2a). Genotyping PCR with primers targeting regions flanking

the deleted exon revealed a product of 761 bp in the knockout cells as compared to 1205-bp in the parental condition. The production of an out of frame product led to the complete loss of the protein from the cells, as can be seen for all four cell lines in Fig. 2a. Thus, we were able to produce cellular model systems to study the functional consequences of *ARID1A* loss in the context of other commonly occurring mutations.

After generating the *ARID1A*-deficient cell lines, we next sought to characterize them phenotypically. Surprisingly, in contrast to its described tumor suppressive role, we observed that the deletion of *ARID1A* led to a severe impairment in proliferation in two cell lines (HCT116 and DLD1) while proliferation in the other two cell lines (COLO320DM and HT29) was unaffected (Fig. 2b). Thus, loss of *ARID1A* differentially affects colorectal cancer cell proliferation.

### *ARID1A* is required for MEK/ERK pathway-induced transcription

To identify the gene regulatory networks responsible for the observed proliferation defects, we performed analyses of mRNA-sequencing data in HCT116 and DLD1 parental and *ARID1A*-deleted cell lines. Since the BAF complex




**Fig. 2** The loss of ARID1A impairs proliferation of a subset of colorectal cancer cell lines. To mimic *ARID1A*-deficient colorectal cancer, we used CRISPR/Cas9-mediated gene editing to delete exon 5 of the *ARID1A* gene from four colorectal cancer cell lines HCT116, DLD1, COLO320DM, and HT29. Regions flanking exon 5 were targeted by two guide RNAs leading to an out of frame gene product. Genotyping PCRs show a shorter product of 761 bp in the *ARID1A* knockout (KO) cells (a, middle panel). This led to a complete loss of the ARID1A protein from the KO cells (a, lower panel). HSC70 is used as a loading control. Representative graphs show that the proliferation of the HCT116 and DLD1 cell lines is significantly impaired by the deletion of *ARID1A*, whereas the proliferation of COLO320DM and HT29 is unaffected by this knockout (b). Error bars represent standard deviation between the replicates. *n* for proliferation assay = 2, \**p* < 0.05 unpaired *t* test

has primarily been described to be a transcriptional activator and function in enhancer activation, we focused on genes that were downregulated upon ARID1A loss to identify potential direct transcriptional targets. Pathway enrichment analysis for the set of downregulated genes in each of these cell lines (Additional file 1: Figure S1d) revealed considerable variability between the three cell lines. Notably, the two cell lines displaying proliferation defects (HCT116 and DLD1) showed an overlap of 48 downregulated genes upon *ARID1A* KO (Fig. 3a). While in the HCT116 cell line several transcriptional regulatory pathways were affected, COLO320DM cells (whose proliferation was unaffected by *ARID1A* loss) displayed changes in gene expression associated with cardiac differentiation and Wnt pathway.

Further gene set enrichment analyses (GSEA) revealed that genes controlled by MEK/ERK pathway components (EGFR, MEK, and ERK) were specifically downregulated

following ARID1A loss in HCT116 (EGFR, MEK) and DLD1 (KRAS) cells (Fig. 3a). This finding is consistent with these cell lines both containing mutations in the *KRAS* gene. To further investigate whether ARID1A may preferentially promote the expression of downstream *KRAS* target genes, we compared three *KRAS*-mutated cell lines (DLD1, HCT116, T84) to three wild-type counterparts (COLO320DM, HT29, RKO) using the Morpheus tool [39]. We identified *EREG*, *F3*, and *JAG1* as potential candidates that were particularly highly expressed in the *KRAS*-mutated cell lines compared to cell lines harboring wild-type *KRAS* (Fig. 3b). Notably, the three *KRAS*-mutated CRC cell lines all harbored activating mutations at residues G12 or G13. While not previously characterized as typical downstream MEK/ERK targets, each of these genes has potential interesting roles in the development of cancer. EREG (Epiregulin) is a ligand for EGFR (epidermal growth factor receptor) which signals through the MEK/



**Fig. 3** Loss of *ARID1A* results in deregulated expression of MEK/ERK pathway target genes. Forty-eight genes are commonly downregulated in the HCT116 and DLD1 cell lines (a). Gene set enrichment analysis shows that gene sets containing targets of the MEK/ERK pathway are enriched in the parental condition (a). The genes *EREG*, *F3*, and *JAG1* are highly expressed in cell lines with *KRAS*<sup>G13D</sup> mutations as analyzed using on the Morpheus tool to analyze data from the Cancer Cell Line Encyclopedia (CCLE) [36] (b). The scale represents the minimum expression in a particular row (blue) to the maximum expression in that row (red). Treatment with 20 nM trametinib for 24 h leads to a reduction of phosphorylated ERK (pERK) (c). The expression of *EREG*, *F3*, and *JAG1* was significantly reduced by trametinib treatment and *ARID1A* deletion. Treatment with trametinib in *ARID1A*-deficient cells did not lead to a further reduction of gene expression (d). *ARID1A* mutations are significantly mutually exclusive with *KRAS* mutations in the TCGA colorectal cancer patient cohort (e). The y-axis represents  $-\log_{10}(p \text{ value})$  and the blue dots represent significantly mutually exclusive or co-occurring mutations. pERK and JUND levels remain unchanged in *ARID1A*-deficient cells. HSC70 is used as a loading control. The AP1 transcription network gene set [41] is enriched in the parental condition (f). qRT-PCRs were performed for biological triplicates and technical duplicates. Error bars represent the standard deviation between three biological replicates. Significance was calculated using an unpaired *t* test, \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001



ERK pathway [40]. One study suggested that low EREG expression is associated with better overall survival in colorectal cancer patients [41]. *F3* (tissue factor III) encodes a glycoprotein receptor for coagulation factor VII and initiates blood coagulation, but has also been implicated in cancer metastasis [42]. *JAG1* (Jagged1) is a ligand for the Notch receptor, and high expression has been associated with poor prognosis in CRC [43]. To test whether these genes are, in fact, targets of the MEK/ERK pathway, we inhibited the pathway by treating cells with the clinical MEK1/2 inhibitor trametinib. Treatment with 20 nM trametinib for 24 h reduced the levels of phosphorylated ERK completely (Fig. 3c), thus blocking the activation of downstream targets of this pathway. Consistent with their co-expression in *KRAS*-mutated CRC cell lines, *EREG*, *F3*, and *JAG1* were all downregulated following trametinib treatment, thereby confirming that they are, indeed, MEK/ERK target genes (Fig. 3d). Importantly, consistent with our GSEA analyses, all three investigated MEK/ERK target genes were also downregulated by the loss of *ARID1A*. Furthermore, consistent with *ARID1A* functioning epistatically downstream of the *KRAS*-dependent MEK/ERK signaling, trametinib did not substantially further reduce the expression of these genes in the absence of *ARID1A* expression. Therefore, our results suggest that *ARID1A* is required for maintaining the expression of cancer-relevant downstream targets of the MEK/ERK pathway in *KRAS*-mutated CRC cells.

#### ***ARID1A* is essential in *KRAS*-mutated colorectal cancer cells and controls the MEK/ERK pathway at the transcriptional level**


Based on our results above, indicating a positive role for *ARID1A* downstream of the MEK/ERK pathway, we reasoned that mutations of *ARID1A* and *KRAS* would not be compatible since a loss of *ARID1A* would impede the effects of hyperactive MEK/ERK signaling. Indeed, examination of the TCGA PanCancer Atlas colorectal adenocarcinoma cohort revealed that *KRAS* mutations were mutually exclusive with *ARID1A* mutations with only 16 out of 526 patients harboring mutations in both genes (Fig. 3e, Additional file 1: Figure S1b). This mutual exclusivity was even more pronounced when the analysis was restricted to *KRAS* mutations in the codons for residues G12 and G13 (Additional file 1: Figure S1b). Interestingly, the mutation rates of 17% for *ARID1A* are significantly higher in *KRAS*-wildtype tumors than in *KRAS*-G12/G13-mutated samples. This finding is consistent with our in vitro findings that the *KRAS*-mutant colorectal cancer cells HCT116 and DLD1 (*KRAS*<sup>G13D</sup> mutation) displayed proliferation defects (Fig. 2b) upon the loss of *ARID1A*. Therefore, in the context of *KRAS* mutations, *ARID1A* does not appear to function tumor

suppressive, but rather facilitates the expression of genes particularly dependent on the MEK/ERK pathway.

To further explore *ARID1A* function in the *KRAS*-mutant context, we investigated whether *ARID1A* loss directly regulated MEK/ERK pathway signaling activity by examining the levels of phosphorylated ERK (pERK) in wild-type and *ARID1A*-deficient HCT116 cells. However, loss of *ARID1A* expression did not result in decreased phosphorylation of ERK in either HCT116 (Fig. 3f) or DLD1 cells (Additional file 1: Figure S1c). Moreover, the expression of one of the most highly expressed AP1 factors, *JUND*, was also unaffected by *ARID1A* loss in either HCT116 (Fig. 3f) or DLD1 cells (Additional file 1: Figure S1c), suggesting that the observed perturbation of downstream MEK/ERK target genes was not due to altered expression of *JUND*. We therefore reasoned that *ARID1A* may control the transcriptional activation capacity of AP1 transcription factors and tested this hypothesis by performing GSEA using a set of genes associated with the AP1 transcription network [44]. Consistent with our hypothesis, this gene set was specifically downregulated in *ARID1A*-deficient HCT116 and DLD1 cells in comparison with the parental cell lines (Fig. 3g). Thus, together, these findings suggest that *ARID1A* regulates target gene expression of the MEK/ERK pathway directly at the transcriptional level without appreciably affecting upstream signaling.

#### ***ARID1A* localizes to AP1-bound enhancer regions**

We next sought to examine the direct roles of *ARID1A* in controlling transcription downstream of the MEK/ERK pathway by examining the genome-wide occupancy of *ARID1A*. To date, most conclusions about *ARID1A* function in transcription have been through indirect information based on SMARCA4 and SMARCC1 occupancy. Thus, in order to gain further direct, causal insights, we established chromatin immunoprecipitation for *ARID1A* utilizing a recently established dual cross-linking approach [45]. This approach yielded good quality ChIP-seq data, enabling the direct examination of *ARID1A* occupancy. Bioinformatic analysis of these data confirmed a strong overlap with the BAF complex subunits SMARCA4 and SMARCC1 and co-occupancy with H3K27ac, which specifically marks active enhancer and promoter regions (Fig. 4a). Furthermore, consistent with recent literature demonstrating the importance of the BAF complex in enhancer-mediated regulation, the majority of *ARID1A*-enriched regions were distal (5 to > 500 kb) to the nearest transcriptional start site (TSS) (Fig. 4b). To further examine *ARID1A* function at enhancer regions, we specifically identified active, *ARID1A*-bound regions which were enriched for H3K27ac and contained accessible chromatin regions



**Fig. 4** ARID1A is localized to AP1-occupied enhancers. ARID1A co-localizes with the BAF complex subunits SMARCA4 and SMARCC1 as well as the active mark H3K27ac. The heatmaps represent all ARID1A binding sites ordered in descending order of ARID1A occupancy (a). ARID1A localizes mainly to regions that are distal to transcription start sites (TSS) with the maximum number of peaks between 5 and 500 kb of TSSs (b). ARID1A-bound enhancers were defined based on overlap of ARID1A with H3K27ac and ATAC-seq. From these regions, any annotated TSSs were subtracted and 3061 ARID1A-bound enhancers were identified (c). Motif analysis on ARID1A-bound enhancers shows enrichment for the Jun-AP1(bZIP) motif (d). ReMap analysis shows that several AP1 transcription factors such as FOSL1, FOSL2, FOS, and JUND are enriched on ARID1A-occupied regions identified in HCT116 cells (e). Co-localization of JUND and FOSL1 at ARID1A-bound enhancers in HCT116 cells is shown. The heatmaps represent the 3061 ARID1A-bound enhancers in descending order of ARID1A occupancy (f)

(based on ATAC-seq) (Fig. 4c). To specifically examine ARID1A function at enhancers, we further subtracted any regions that were annotated as transcriptional start sites, yielding 3,061 potential ARID1A-bound enhancer regions. Subsequently, we performed sequence-based motif analyses on these regions to identify enriched DNA-binding sequences indicative of specific transcription factor dependencies. Consistent with our hypothesis and previous studies examining BAF occupancy in other systems [21, 28], we observed that ARID1A-bound enhancers are particularly enriched in AP1 binding motifs

(Fig. 4d). This finding was confirmed by comparing the ARID1A-bound regions with publicly available ChIP-seq data using the ReMap tool, where AP1 factors were among the top hits that co-localize with ARID1A (Fig. 4e). Importantly, among the overlapping factors were FOSL1 and JUND, which are among the most highly expressed AP1 factors in HCT116 cells. We confirmed these findings using ChIP-seq data for FOSL1 and JUND occupancy in HCT116 cells, where we observed a strong co-occupancy of FOSL1 and JUND at the 3,061 ARID1A-bound enhancer regions (Fig. 4f). Motif

analysis and ReMap-based transcription factor occupancy for all ARID1A binding sites are shown in Additional file 1: Figure S2a, b. Thus, in conclusion, global ChIP-seq analysis revealed that ARID1A co-localizes with AP1 factors, thereby supporting a potential direct role of ARID1A in directing AP1-dependent enhancer-mediated gene regulation downstream of the MEK/ERK pathway.

#### **The loss of ARID1A leads to a significant reduction of H3K27ac at enhancers and downregulation of target genes**

After identifying potential ARID1A-bound enhancers and confirming that they are indeed co-occupied by the AP1 factors, we utilized available Hi-C and H3K27ac occupancy data from HCT116 cells to identify potential target genes based on their activity (i.e., H3K27ac-enriched TSS) and presence in the same topology-associated domain. Using this approach, we identified 6,741 genes associated with the 3,061 potential enhancers. Further overlap of these genes with those downregulated following *ARID1A* deletion in HCT116 cells yielded 317 potential direct enhancer targets, including several interesting cancer-relevant genes (Fig. 5a). Interestingly, the *EREG*, *F3*, and *JAG1* genes, which we had identified as being highly dependent on the MEK/ERK pathway, were also identified as ARID1A-bound enhancer targets. Consistently, as shown before, these genes were downregulated by the knockout of *ARID1A* in both *KRAS*-mutated cell lines HCT116 and DLD1 (Fig. 5b). The ChIP-seq tracks shown in Fig. 5c confirm that the ARID1A-occupied enhancer regions on all three genes were also occupied by the AP1 transcription factor JUND and marked by H3K27ac. Importantly, these potential enhancer-promoter pairs are located within the same topologically associated domain (TAD) as assessed by Hi-C, making their interaction more probable. Moreover, PRO-seq (precision run on sequencing) data revealed nascent RNA transcription from these sites, suggesting that eRNAs might be transcribed from these enhancers. These enhancers were also accessible as assessed by ATAC-seq. Contrary to the prevailing view that ARID1A is essential for the maintenance of open chromatin, the loss of ARID1A did not lead to a decrease in accessibility at ARID1A-bound enhancers in HCT116 cells (Fig. 5c, Additional file 1: Figure S2c). While this is surprising, another recent study also reported no reduction of accessibility at enhancers upon the loss of ARID1A in RMG1 cells [46]. Nevertheless, there is a striking loss of H3K27ac from these enhancers, which could partially explain the loss of target gene expression. We confirmed the H3K27ac reduction by ChIP-qPCR at these enhancers (Fig. 5d) and also observed a similar reduction at all ARID1A-bound

enhancers (Additional file 1: Figure 2c). Thus, our results show that the loss of ARID1A leads to the reduction of activity of enhancers and target gene expression at regions co-occupied by AP1 transcription factors.

#### **Attenuation of the MEK/ERK pathway leads to a reduction of ARID1A and H3K27ac at enhancers**


To further confirm the link between the MEK/ERK signaling pathway and the loss of activity of enhancers, we attenuated the pathway using the clinical MEK1/2 inhibitor trametinib. ChIP-qPCR for JUND at these enhancers confirmed that the MEK/ERK pathway is essential for the maintenance of JUND AP1 transcription factor occupancy at these enhancers (Fig. 6a). Moreover, consistent with our model, treatment with trametinib also resulted in reduced occupancy of ARID1A and H3K27ac at these enhancers (Fig. 6b, c). Thus, inhibition of AP1 transcription factor activity by blocking the upstream MEK/ERK pathway effectively leads to reduced ARID1A recruitment and decreased histone acetylation at ARID1A/AP1-bound enhancers, leading to decreased target gene expression.

#### **Discussion**

The importance of epigenetic regulators in cancer has been widely recognized, and much of the current research is focused on deciphering the role of these regulators in driving oncogenic programs in cancer cells. As described in the previous sections, subunits of the BAF complex are among the most frequently mutated genes in cancer and are extensively described as tumor suppressors. In this study, we explored the role of ARID1A in transcriptional control of gene expression in colorectal cancer cells. We found that cell lines containing activating *KRAS* mutations are particularly dependent on ARID1A. In the absence of ARID1A, the proliferation of these cells is severely impaired, suggesting a tumor-supporting function in this context. Furthermore, we confirmed that ARID1A itself is, indeed, mainly localized at enhancers in colorectal cancer cells where it acts as a co-factor at regions bound by AP1 transcription factors, which act downstream of the MEK/ERK pathway. Consistently, we further showed that the attenuation of the MEK/ERK pathway leads to a disruption of this transcriptional network at enhancers as both ARID1A and H3K27ac are lost from these sites. This is accompanied by a downregulation in the expression of the associated target genes.

At the molecular level, ARID1A acts as a cofactor at sites occupied by AP1 transcription factors. Consistent with our findings, a direct interaction between ARID1A and FOS AP1 factors was previously reported [28]. Our work suggests that this interaction is especially relevant in *KRAS*-mutated colorectal cancers, where an






**Fig. 5** The loss of ARID1A leads to a loss of enhancer activity. Six thousand seven hundred forty-one genes associated with ARID1A-bound enhancers were determined. Three hundred seventeen genes were also downregulated by the knockout of ARID1A. Among these were the EREG, F3, and JAG1 genes (a). The three MEK/ERK pathway target genes identified were downregulated by the deletion of ARID1A in both KRAS-mutated cell lines (HCT116 and DLD1) (b). At the genomic loci for these genes, we identified potential enhancers which are occupied by ARID1A, JUND, and H3K27ac within the same topologically associated domains (TAD). Vertical dotted lines represent TAD boundaries. The potential enhancers are also accessible as assessed by ATAC-seq and are transcriptionally active as assessed by PRO-seq (c). There is a significant reduction of H3K27ac at these enhancers upon the deletion of ARID1A (c, d). qRT-PCRs for gene expression and ChIP were run in biological triplicates and technical duplicates. The dotted lines represent the average ChIP-qPCR signal for the negative control IgG. Error bars represent the standard deviation between three biological replicates. Significance was calculated using unpaired t test, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001

attenuation of the MEK/ERK pathway mimics the effects of ARID1A loss in these cells. Surprisingly, the primary function of ARID1A at these regions does not appear to be dependent upon the ability of the BAF complex to remodel chromatin since its loss had no effect on chromatin accessibility. This may be partially explained by other BAF complexes containing orthologues of ARID1A

which may enable chromatin remodeling function [47], but not be sufficient for enhancer activation, or due to the binding of other transcription factors that help maintain chromatin in an accessible conformation. Instead, the ARID1A-containing BAF complexes appear to facilitate the assembly of a larger coactivator complex essential for the activation of enhancers (for instance,



through recruitment of a histone acetyltransferase-containing complex). This effect is consistent with what has been reported in *Smarca1*-deleted mouse embryonic fibroblasts, where H3K27ac is also globally lost from enhancers. Re-expression of *Smarca1* in that system restored H3K27ac, p300, BRD4, and Mediator binding in

the chromatin fraction, supporting that enhancer activity could be restored [32]. In addition to its requirement for the placement of H3K27ac, as a large multi-subunit complex, ARID1A might also facilitate enhancer activity by promoting chromatin looping between the promoter and enhancer. As a complex with many subunits, it

appears likely that BAF may play a role in the aggregation of cofactors at enhancers, thereby forming locally active transcriptional hubs.

Under the notion that *ARID1A* is a tumor suppressor, several research groups sought to model *Arid1a*-deficient cancer in mice. While these models confirmed its tumor suppressive role in various cancers, some striking observations were made which indicated that *ARID1A* could also play a pro-tumorigenic role in certain contexts. For example, in ovarian epithelial cancer (OEC), while *Pten/Apc* deletion led to the formation of poorly differentiated OECs in mice, the additional deletion of *Arid1a* caused tumor cells to have a less aggressive, more differentiated epithelial phenotype [48]. Similarly, deletion of *Arid1a* from otherwise wild-type mice protects against DEN (diethylnitrosamine)-induced hepatocellular carcinoma (HCC), while overexpression of *Arid1a* accelerated tumor initiation [49]. In a pancreatic cancer model, *Arid1a* was shown to have very context-dependent roles [23]. In colorectal cancer, the deletion of *Arid1a* in the background of *Apc* inactivation (which hyperactivates the Wnt pathway) blocked tumor formation [21]. Similarly, deletion of the BAF component *Smarca4* also attenuated Wnt-dependent tumorigenesis [50]. Interestingly, we also observed a strong colocalization of *ARID1A* with the downstream effector of the Wnt pathway, *TCF7L2* (Fig. 4 a), which could explain the cooperation between these factors at the transcriptional level. Thus, the consequences of *ARID1A* loss in cancer appear to be particularly context-dependent. We show that, in the background of *KRAS* mutation, the loss of *ARID1A* has an inhibitory effect on proliferation. This finding is further confirmed by the fact that mutations in *KRAS* and *ARID1A* are largely mutually exclusive in colorectal cancer patients. In future studies, it will be very interesting to decipher at which time point during transformation cancer cells lose *ARID1A* expression. In colorectal cancer, it appears that loss of *ARID1A* in wild-type backgrounds may promote early tumorigenesis while loss of *ARID1A* in the background of mutations in *APC* or *KRAS* may inhibit tumor progression (Fig. 6d).

Overall, these findings indicate that the context in which *ARID1A* loss occurs likely determines whether it plays a primarily tumor suppressive or tumor promoting role. Several BAF complex subunits have been described as tumor suppressors in different contexts, making it difficult to use them as direct therapeutic targets. Therefore, several studies have successfully sought to identify synthetic lethal therapeutic targets and identified vulnerabilities that can, at least in principle, be targeted using small molecule inhibitors. While these have shown some promise [22, 26, 51–54], it has become increasingly clear that the context of the tumor must be considered carefully before applying these therapies to *ARID1A*-deficient cancers. In the case

of oncogenic functions, such as in synovial sarcoma or in colorectal cancer as described here, directly targeting the BAF complex could be an option. This could possibly be mediated using PROTACS (Proteolysis Targeting Chimera), which lead to targeted degradation of a cellular protein. Consistently, a PROTAC targeting the BRD9 subunit of the BAF complex has already shown promise in models of synovial sarcoma [55]. Thus, the development of additional PROTACS mediating the degradation of the BAF complex may provide new therapeutic approaches for *KRAS*-mutated colorectal cancer. This would enable a precision oncology approach for the therapy of a relevant fraction of colorectal cancers based on robust molecular mechanisms.

## Conclusions

Taken together, our work significantly expands the knowledge about the context-dependent functions of *ARID1A* in cancer. We identified that *ARID1A* is essential in specific contexts of colorectal cancers and was able to show mechanistically that *KRAS*-mutated colorectal cancer cells are especially dependent on the presence of *ARID1A*. In cells containing *KRAS* mutations, the loss of *ARID1A* led to decreased activity of enhancers bound by *ARID1A* and the AP1 transcription factors, and deregulation of target gene expression. This effect was accompanied by impaired proliferation of these cells. Moreover, we also showed that *ARID1A* has roles beyond its chromatin remodeling activity and can serve as a transcriptional cofactor to promote histone acetylation. This work builds upon and expands existing knowledge about the interplay of *ARID1A* and AP1 transcription factors by showing its relevance in the development of a subset of colorectal cancers. We also suggest the possibility of the BAF complex being a targetable entity in these cancers. Further exploration of this concept might provide additional important insights into the mechanisms by which *ARID1A*-containing BAF complexes regulate enhancers and serve as a knowledge base that can be exploited for therapeutic benefit.

## Methods

### Patient data and immunohistochemistry

These experiments were performed according to the guidelines of the local ethics committee and with the requisite informed consent from all patients. Treatment naïve rectal cancer biopsies from 182 patients who were treated at the Department of General and Visceral Surgery, University Medical Center Göttingen, Germany, were collected and tissue microarrays were prepared. Immunohistochemistry for *ARID1A* was performed on these tissues. The slides were de-paraffinized, rehydrated, and then incubated for 6 min in a pressure cooker (Pascal, Dako) with EDTA and Tween 20 pH 8.

After cooling down, the slides were washed and incubated in 3% H<sub>2</sub>O<sub>2</sub> for 10 min. After washing the slides again, these were incubated with ARID1A antibody (Cell Signaling, 1:500) overnight at 4 °C. The next day, the slides were incubated with the boost-HRP secondary antibody (Cell Signaling) and stained using 3,3'-diaminobenzidine (DAB) (Medac) for 8 min at RT. Counterstaining was performed with hematoxylin. The slides were imaged using an Axioscope microscope (Carl Zeiss). The staining intensities of 164 biopsies were scored by a board-certified pathologist (P.S.).

### Cell culture

HCT116 and HT29 cells were cultured in McCoy's 5A medium (Gibco), and DLD1 and COLO320DM cells were cultured in RPMI 1640 (Gibco). All cells were tested to be mycoplasma free. All media were supplemented with 10% FBS, 1% glutamine, and 100 U/mL penicillin/streptomycin. Cells were maintained at 37 °C and 5% CO<sub>2</sub>.

For proliferation assays, 5000–7500 cells were seeded in 24-well plates in multiple replicates. Cell proliferation was assessed by measuring confluence using a Celigo S Cell Imaging Cytometer (Nexcelom) every 24 h for 5 days, and plotted as relative confluence over time. The confluence in each well on each day was normalized with the confluence in that well on day one.

For treatment with trametinib (Biomol GmbH), 20 nM of inhibitor was prepared in DMSO and diluted in media. As control, cells were treated with DMSO at a 1:1000 dilution.

### Crystal violet staining

Different conditions were set up in a 24-well format, and cells were grown for 5–7 days. Once confluent, the wells were washed with PBS, fixed in 99% methanol for 10 min, and stained with 1% crystal violet prepared in 2% ethanol.

### Genotyping PCR

Each PCR reaction was conducted in a volume of 25 µL containing 10X buffer B (NEB), dNTPs (Jena Bioscience GmbH), MgCl<sub>2</sub> (NEB), forward and reverse primers (Sigma), and Taq polymerase (Solis Biodyne). The reaction allowed 15 min of initial denaturation followed by 35 cycles of 30 s at 95 °C for denaturation, 45 s at 60 °C for annealing, and 60 s at 72 °C for elongation. Final elongation was carried out at 72 °C for 10 min. The PCR products were run on a 1% agarose gel at 100 V for 45 min and visualized using an INTAS imager.

### Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated in triplicate using the QIAzol<sup>®</sup> lysis reagent (Qiagen) according to the manufacturer's

instructions. One microgram of RNA was used for reverse transcription by MuMLV reverse transcriptase (NEB) to prepare cDNA. Quantitative real-time PCR was carried out using SYBR Green I (Roche Diagnostics GmbH) as a fluorophore with the following conditions: initial denaturation at 95 °C for 2 min followed by 40 cycles of denaturation at 95 °C for 10 s and annealing and extension at 60 °C for 30 s. qPCRs were analyzed using the standard curve method. For each gene, the expression was normalized to the expression of GAPDH [56]. Primers were designed using NCBI primerblast, and primer sequences are indicated in Additional file 2: Table S2.

qPCR primers for ChIP were designed for the indicated enhancer regions. The following conditions were then used: initial denaturation at 95 °C for 2 min followed by 45 cycles of denaturation at 95 °C for 10 s and annealing and extension at 60 °C for 30 s. Primer sequences are indicated in Additional file 2: Table S2.

### Western blot

Cells were lysed in RIPA lysis buffer (0.5% sodium deoxycholate (*w/v*), 0.1% SDS (*w/v*), 1% NP-40 (*v/v*) containing protease inhibitors). The proteins were denatured by adding Laemmli buffer (375 mM Tris/HCl, 10% SDS, 30% glycerol, 0.02% bromophenol blue, 9.3% DTT) and heating at 95 °C for 5 min. These were then resolved by SDS-PAGE and transferred to nitrocellulose membranes, incubated with primary antibodies (Additional file 2: Table S3) overnight at 4 °C and then in secondary antibodies (Additional file 2: Table S3) for 1 h at RT. The blots were developed using a BioRad ChemiDoc<sup>™</sup> imager.

### CRISPR/Cas9-mediated knockout of ARID1A

CRISPR/Cas9-mediated gene editing was used to generate ARID1A-knockout colorectal cancer cell lines to mimic ARID1A-deficient cancer cells. Four cell lines, namely HT29, HCT116, DLD1, and COLO320DM, were used. Guide RNAs targeting the two introns flanking exon 5 of the ARID1A gene were designed, and off-target binding effects were minimized on the basis of scores obtained on the MIT CRISPR design software (<http://crispr.mit.edu/>). The deletion of the flanked exon (which contained a number of nucleotides not divisible by 3) was predicted to lead to a frameshift in any resulting spliced transcript, thereby leading to the loss of protein expression. The guide RNAs were cloned into a pSpCas9(BB)-2A-GFP (PX458) plasmid which was a gift from Feng Zhang (Addgene plasmid # 48138; <http://n2t.net/addgene:48138>; RRID: Addgene\_48138) [75]. Plasmid DNA (4 µg) was transfected into the cells by electroporation using a Lonza Nucleofector according to the manufacturer's instructions. Cells were sorted 48 h after transfection as 192 single cell clones by fluorescence-activated cell sorting based on GFP-positivity. The single cell clones were expanded and



selected for *ARID1A* knockout. A single clone for each cell line was used for all experiments. Further information on the plasmid and gRNAs is provided in Additional file 2: Table S4.

#### Chromatin immunoprecipitation (ChIP)

ARID1A ChIP-seq was performed using a dual-crosslinking approach as described [45]. Briefly, confluent HCT116 cells in 15 cm plates were crosslinked for 20 min in 15 mM EGS (Thermo Fisher Scientific), 20 min in 2 mM EGS at RT, and then in 1% paraformaldehyde (Electron Microscopy Sciences) for 40 min at 4 °C. The samples were then processed using the Active Motif ChIP-IT High Sensitivity Chromatin Immunoprecipitation kit. The samples were sonicated in a Bioruptor Pico (Diagenode) for 15 cycles (30 s on/off) to obtain 200–500 bp fragments. Ten micrograms of sheared chromatin were used for immunoprecipitation overnight with 5 µL of ARID1A antibody (Additional file 2: Table S3, Cell Signaling) at 4 °C. The immunoglobulin complexes were isolated using protein G agarose beads. The beads were washed, and the chromatin was de-crosslinked in the presence of proteinase K at 65 °C overnight. DNA was extracted according to the manufacturer's instructions.

For H3K27ac and JUND ChIP, confluent cells in 15-cm plates were crosslinked for 20 min by adding 1% formaldehyde (Sigma). For ARID1A ChIP-qPCR, confluent cells in 15-cm plates were crosslinked in 2 mM EGS (Thermo Fischer Scientific) for 40 min at RT followed by crosslinking with 1% paraformaldehyde (Electron Microscopy Sciences) at 4 °C for 40 min. The samples were processed further as follows. Glycine (125 mM) was added to quench the formaldehyde/paraformaldehyde. The cells were harvested in nuclear preparation buffer (150 mM NaCl, 20 mM EDTA pH 8.0, 50 mM Tris-HCl pH 7.5, 0.5% NP-40, 1% Triton X-100, 20 mM NaF, PIC). The nuclear pellet was isolated and resuspended in 150–300 µL sonication buffer-1 (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS (*w/v*), PIC). After allowing lysis, the SDS content was diluted to 0.5% SDS using 150–300 µL sonication buffer-2 (20 mM EDTA, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40 (*v/v*), 20 nM NaF). The samples were sonicated in a Bioruptor Pico (Diagenode) for 15 cycles (30 s on/off). The soluble chromatin was pre-cleared with unconjugated sepharose. The chromatin was then diluted in dilution buffer (20 mM EDTA, pH 8.0 50 mM Tris-HCl, 150 mM NaCl, 1% (*v/v*) NP-40, 20 mM NaF 0.5% (*w/v*), sodium deoxycholate) and incubated overnight with primary antibodies (Additional file 2: Table S3). Immunoglobulin-bound complexes were precipitated by adding Protein A sepharose. The beads were washed, the chromatin was de-crosslinked at 65 °C overnight, and DNA was isolated by phenol-chloroform extraction.

#### RNA-seq and ChIP-seq library preparation and sequencing

RNA integrity was confirmed by agarose gel electrophoresis. Libraries for poly(A) mRNA-sequencing were prepared using the Capture and Amplification by Tailing and Switching (CATS) RNA-seq kit (Diagenode) according to the manufacturer's protocol using 50 ng total RNA as the starting material. For ChIP-seq libraries, the Diagenode MicroPlex Library Preparation Kit v2 was used according to the manufacturer's instructions. Fifty bp single-end mRNA-sequencing was performed by Diagenode, Seraing, Belgium, on a HiSeq 2500. ChIP-seq libraries were sequenced by the Transcriptome and Genome Analysis Laboratory (TAL) of the University of Göttingen on the HiSeq 4000 (50 bp single-end). The concentrations of the libraries were measured using the Qubit 2.0 fluorimeter (Invitrogen), and fragment size was assessed using a Bioanalyzer (Agilent).

#### Bioinformatic analysis

##### mRNA-seq data processing

Fastq files for newly generated data have been deposited in ArrayExpress under the accession number E-MTAB-7791. Publicly available raw data (for *ARID1A*-deficient HCT116 cells) was downloaded from the NCBI GEO database (accession numbers are provided in Additional file 2: Table S1). The quality of the sequencing was determined using FASTQC. These were trimmed using specific trimming conditions suggested by the CATS manual. The trimmed fastq files were mapped to the hg19 version of the human genome with Bowtie2 (v 2.2.5) under the TopHat module using the --very sensitive end-to-end setting [57]. The abundances of the various transcripts in the obtained BAM files were estimated by CuffLinks, and differential expression analysis between different conditions was carried out using CuffDiff [58]. For further analysis in differential expression, those genes which showed *q* value  $\leq 0.05$ ,  $\log_2FC \geq 0.7$ , or  $\leq -0.7$  for HCT116 and  $\log_2FC \geq 0.6$  or  $\leq -0.6$  for DLD1 and COLO320DM were used.

##### ChIP-seq and ATAC-seq data processing

Fastq files were obtained from the Transcriptome and Genome Analysis Laboratory (TAL) of the University Medical Center Göttingen (the data is deposited in ArrayExpress under the accession number E-MTAB-7792). Publicly available raw data were downloaded from NCBI GEO database (accession numbers are provided in Additional file 2: Table S1). The quality of the sequencing was determined using FASTQC. The first 12–13 bp from the 5' end were trimmed using FASTX trimmer where necessary. The trimmed fastq files were mapped to the hg19 version of the human genome with Bowtie 2 (v 2.2.5) using the --very sensitive end-to-end setting [57]. The BAM files obtained were sorted and indexed

using SAMTOOLS [59]. In the ATAC-seq datasets, mitochondrial reads were removed. These files were converted to BigWig format using BamCoverage [60] and visualized using the Integrated Genome Viewer (IGV) tool [61]. Coverage was normalized to 1X setting, and an extension length of 200 bp was used (for ChIP-seq datasets, ATAC-seq data was paired-end and was not extended). Peaks were called using the MACS2 software [62], and BED files were obtained. The `--nomodel` setting was used, and the FDR  $q$  value to call peaks was set at  $\leq 0.05$ . Broad peaks (cutoff of 0.05) were called for histone modifications and narrow peaks for transcription factors and ATAC-seq data.

#### Functional analysis and integration of ChIP-seq and RNA-seq data

The GeneVenn online tool was used to create Venn diagrams of gene lists. Processed RNA-seq data was subjected to Gene Set Enrichment Analysis (GSEA) [63, 64]. Gene Ontology (GO) and pathway enrichment analysis were performed using the EnrichR software [65, 66] using lists of downregulated genes as input. HOMER (v 4.8) was used to find motifs enriched in ChIP-seq datasets [67]. Scrambled sequences of the input file were used as background. The Genomic Regions Enrichment of Annotations Tool (GREAT) was used to find region associations [68]. Associated genes were determined by using a custom-made algorithm considering TAD boundaries from Hi-C data as well as gene activity based on H3K27ac ChIP-seq data. The ReMap analysis tool was used to find co-localizing transcriptional regulators using a BED file as input [69]. Heatmaps and aggregate plots were created using the reference point mode of the computeMatrix deepTools tool followed by plotProfile or plotHeatmap [60]. Profiles and heatmaps were plotted relative to the center of the peaks provided in the input BED file  $\pm 5$  kb.

#### Hi-C and PRO-seq data processing

Fastq files were downloaded from NCBI GEO (accession numbers in Additional file 2: Table S1). The Hi-C data was analyzed using HiCExplorer [70]. Briefly, reads were mapped against hg19 with bwa [71], and then a matrix was built with 2 kb resolution. Subsequently, corrections of the matrix were done to remove bias of GC, open-chromatin, and number of restriction sites within a certain bin. The corrected matrix was then used to call TADs (topologically associated domains).

The PRO-seq data was analyzed as previously described [72]. The reads were first mapped against hg19 with bowtie2 [57]. The low-quality mapped reads ( $MQ < 30$ ) were discarded, and the duplicates were removed. BAM files were then converted to bedGraph format, and only the 3' ends of fragments were kept to achieve single-base

resolution. Next, bedGraph files were converted to bigwig files for visualization of nascent transcription.

#### Statistical analyses and graphs

Graphs and tables for Figs. 1a and 3e and Additional file 1: Figure S1b were generated from the cBioPortal for Cancer Genomics [3, 4]. For calculating statistical significance to compare parameters between different conditions, the unpaired  $t$  test was used.  $P$  values were determined by this test and significance depicted as  $***p \leq 0.001$ ,  $**p \leq 0.01$ ,  $*p \leq 0.05$ . Statistical tests for the analysis of NGS data were performed by the indicated software.

#### Additional files

**Additional file 1: Figure S1.** Expression of BAF complex subunits in the four cell lines used in this study (a). Mutual exclusivity of *ARID1A* and *KRAS* (all and specifically at residues G12 and G13) mutations in the colorectal adenocarcinoma patient cohort from the TCGA PanCancer Atlas (b). Levels of pERK and JUND in Parental and *ARID1A* KO DLD1 cells (c). HSC70 was used as a loading control. The top 10 GO terms enriched for genes downregulated by *ARID1A* KO in the HCT116, DLD1, and COLO320 cell lines (d). **Figure S2.** Transcription factors that colocalize at all ARID1A-bound sites. These include several AP1 transcription factors (a). The AP1 binding motif is significantly enriched at all ARID1A-occupied regions (b). At all ARID1A-bound enhancers there is a reduction of SMARCA4 and SMARCC1 occupancy upon the loss of ARID1A (c). ATAC-seq signal remains unchanged and H3K27ac reduces significantly (c). (PDF 126 kb)

**Additional file 2:** Supplementary tables. This file contains supplementary **Tables S1–S4**. (DOCX 31 kb)

#### Acknowledgements

The authors would like to thank the Transcriptome and Genome Analysis Laboratory (TAL), UMG Göttingen, for carrying out next-generation sequencing for this study. The authors would also like to thank N. Molitor for technical assistance and all members of the Johnsen group for constructive discussions.

#### Authors' contributions

SAJ and MS designed the experiments and wrote the manuscript. JG and MG provided input and samples for the human rectal cancer analysis. JE performed IHC staining, P.S. scored the tissue microarray data together with MS. JR and FHH established the CRISPR/Cas9-mediated *ARID1A* deletion strategy under the guidance of SAJ. RLK, EH, and FW provided intellectual input and aided in experimental design throughout the study. AP helped establish the dual crosslinking approach to establish ARID1A ChIP. MS performed the in vitro experiments with help from FHH, FSY, and APK. XW designed and performed some bioinformatic analyses for this study. XW, FHH and APK edited the manuscript. All authors have read and approved the final version of the article.

#### Funding

This work was partially supported by the Göttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences (GGNB) (DFG grant GSC 226).

#### Availability of data and materials

The datasets generated and during the current study are available in the ArrayExpress repository, <https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7791>, <https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7792> under accession numbers E-MTAB-7791 (m-RNA-seq) and E-MTAB-7792 (ChIP-seq).

Publicly available datasets accessed are available in the following:

NCBI GEO: SMARCC1, SMARCA4, H3K27ac ChIP-seq <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71510> [21]

NCBI GEO: FOSL1, JUND ChIP-seq <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32465> [73]

NCBI GEO: ATAC-seq <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101966> [47]

NCBI GEO: HCT116 RNA-seq <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71511> [21]

NCBI GEO: Hi-C and PRO-seq <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104333> [74]

#### Ethics approval and consent to participate

The study was conducted in accordance with the Helsinki Declaration and was approved by the ethics committee of the University Medical Center Göttingen.

#### Consent for publication

All authors give consent for the publication of the manuscript.

#### Competing interests

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, 37075 Göttingen, Germany. <sup>2</sup>Gene Regulatory Mechanisms and Molecular Epigenetics Lab, Gastroenterology Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. <sup>3</sup>Department of Gastroenterology & Gastrointestinal Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany. <sup>4</sup>Department of Pathology, University Medical Center Göttingen, 37075 Göttingen, Germany.

Received: 5 April 2019 Accepted: 29 May 2019

Published online: 19 June 2019

#### References

- GLOBOCAN 2018. World Health Organization. In: Global Health Observatory. Geneva: World Health Organization; 2018.
- Fearon EF, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell*. 1990;61.
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2.
- Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal*. 2013;6.
- Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. *Nat Rev Mol Cell Biol*. 2008;9.
- Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. *J Mol Med*. 1996;74.
- Whitmarsh AJ. Regulation of gene transcription by mitogen-activated protein kinase signaling pathways. *Biochim Biophys Acta - Mol Cell Res*. 2007;1773.
- Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ, Archer TK, et al. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. *Mol Cell Biol* 2000; 20.
- Dallas PB, Cheney IW, Liao DW, et al. p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. *Mol Cell Biol*. 1998;18(6):3596–3603.
- Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MB. Nucleosome disruption and enhancement of activator binding by a human SWI/SNF complex. *Nature*. 1994;370(6489):477–81.
- Imbalzano AN, Kwon H, Green MR, Kingston RR. Facilitated binding of TATA-binding protein to nucleosomal DNA. *Nature*. 1994;370(6489):481–5.
- Phelan ML, Narlikar GJ, Kingston RE. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. *Mol Cell*. 1999;3(2):247–53.
- Chi TH, Wan M, Zhao K, Taniuchi I, Chen L. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. *Nature*. 2002;418.
- Wang X, Werneck MBF, Wilson BG, Kim H-J, Kluk MJ, Thom CS, et al. TCR-dependent transformation of mature memory phenotype T cells in mice. *J Clin Invest*. 2011;121.
- Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, Garbay S, et al. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. *EMBO J*. 2005;24.
- Gao X, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. *Proc Natl Acad Sci USA*. 2008;105.
- Ho L, Jothi R, Ronan JL, Cui K, Zhao K, Crabtree GR. An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. *Proc Natl Acad Sci USA*. 2009; 106(13):5187–91.
- Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. *Nat Genet*. 2013;45.
- Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. *PLoS One*. 2013;8.
- Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. *Cancer Res*. 2011;71.
- Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. *Nat Genet*. 2017;49.
- Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. *Nat Commun*. 2015;6.
- Livshits G, Alonso-curbelo D, Iv JPM, Koche R, Saborowski M, Wilkinson JE, et al. Arid1a restrains Kras-dependent changes in acinar cell identity. *eLife*. 2018;7.
- Huang J, Zhao Y, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. *Genes Chromosomes Cancer*. 2007; 46(8):745–50.
- Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. *Int J Gynecol Cancer*. 2012;22(1):9–14.
- Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. *Cancer Discov*. 2015;5.
- Wang X, Lee RS, Alver BH, Haswell JR, Wang S, Mieczkowski J, et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. *Nat Genet*. 2017;49.
- Vierbuchen T, Ling E, Cowley CJ, Harmin DA, Roberts CWM, Greenberg ME, et al. AP-1 transcription factors and the BAF complex mediate signal-dependent enhancer selection. *Mol Cell*. 2017;68: 1067–1082.e12.
- Lakshminarasimhan R, Andreu-vieyra C, Lawrenson K, Jones PA. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. *Cancer Lett*. 2017;401:11–19.
- Hu G, Schones DE, Cui K, Ybarra R, Northrup D, Tang Q, et al. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. *Genome Res*. 2011;21(10):1650–8.
- Yu Y, Chen Y, Kim B, Wang H, Zhao C, He X, et al. Olig2 targets chromatin remodelers to enhancers to initiate oligodendrocyte differentiation. *Cell Inc*. 2012;152.
- Alver BH, Kim KH, Lu P, Wang X, Manchester HE, Wang W, et al. The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. *Nat Commun*. 2017;8.
- Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of cell type-specific enhancers. *Nat Rev Mol Cell Biol*. 2015;16.
- Raab JR, Resnick S, Magnuson T. Genome-wide transcriptional regulation mediated by biochemically distinct SWI/SNF complexes. *PLoS Genet*. 2015;11.
- Shema-Yaacoby E, Nikolov M, Haj-Yahya M, Siman P, Allemand E, Yamaguchi Y, et al. Systematic identification of proteins binding to chromatin-embedded ubiquitylated H2B reveals recruitment of SWI/SNF to regulate transcription. *Cell Rep*. 2013;4.
- Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. *N Engl J Med*. 2010;363.
- Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Hum Mutat*. 2012;33.

38. Wang XW, Agl NGN, Lowers SF, Weitzig DZ, Allas PBD, Oran EM. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. *Int J Cancer*. 2004;112(4):636.
39. MORPHEUS, <https://software.broadinstitute.org/morpheus>.
40. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe OT, Hanada K. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. *J Biol Chem*. 1995;270(13):7495-500.
41. Kuramochi H, Nakajima G, Kaneko Y, Nakamura A, Inoue Y, Yamamoto M. Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. *BMC Cancer*. 2012;12:88.
42. Morrow JJ, Bayles J, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. *Nat Med*. 2018;24(2):176-85.
43. Sugiyama M, Oki E, Nakaji Y, Tsutsumi S, Ono N, Nakanishi R, et al. High expression of the Notch ligand Jagged-1 is associated with poor prognosis after surgery for colorectal cancer. *Cancer Sci*. 2016;107(11).
44. Rouillard AD, Monteiro CD, Gunderson GW, McDermott MG, Fernandez NF, Wang Z, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. *Database (Oxford)*. 2016.
45. Zirkel A, Nikolic M, Sofiadis K, Mallm JP, Brackley CA, Gothe H, et al. HMGB2 loss upon senescence entry disrupts genomic organization and induces CTCF clustering across cell types. *Mol Cell*. 2018;70.
46. Trizzino M, Barbieri E, Petracovici A, Licciulli S, Zhang R, Gardini A. The tumor suppressor ARID1A controls global transcription via pausing of RNA polymerase II. *Article CellReports*. 2018;23.
47. Kelso TWR, Porter DK, Amaral ML, Shokhiev MN, Benner C, Hargreaves DC. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. *elife*. 2017;6.
48. Zhai Y, Kuick R, Tipton C, Wu R, Sessine M, Wang Z, et al. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. *J Pathol*. 2016;238.
49. Sun X, Wang SC, Wei Y, Yopp AC, Singal AG, Zhu H. Tumor Suppressor Functions in Liver Cancer Article Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. *Cancer Cell* 2017;32.
50. Holik AZ, Young M, Krzystyniak J, Williams GT, Metzger D, Shorning BY, et al. Brg1 loss attenuates aberrant Wnt-signalling and prevents Wnt-dependent tumorigenesis in the murine small intestine. *PLoS Genet*. 2014;10.
51. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med*. 2015;21.
52. Kwan SY, Cheng X, Tsang YTM, Choi J-S, Kwan S-Y, Izaguirre DI, et al. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells. *Oncotarget*. 2016;7.
53. Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. *Nat Cell Biol*. 2017;19.
54. Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. *Oncotarget*. 2014;5.
55. Michel BC, Avino ARD, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. *Nat Cell Biol*. 2018;20(12):1410-20.
56. Tian B, Zhao Y, Kalita M, Edeh CB, Paessler S, Casola A, et al. CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells. *J Virol*. 2013;87.
57. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9.
58. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc*. 2012;7.
59. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. *Bioinformatics*. 2009;16).
60. Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, et al. deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res*. 2016;44.
61. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. *Nat Biotechnol*. 2011;29.
62. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Open Access Model-based analysis of ChIP-Seq (MACS). *Genome Biol*. 2008; 9(9):R137.
63. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide. *Proc Natl Acad Sci*. 2005;102(43):15545-50.
64. Mootha VK, Lindgren CM, Eriksson K, Subramanian A, Sihag S, Lehar J, et al. PGC-1  $\alpha$ -responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet*. 2003;34:267-73.
65. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res*. 2016;44.
66. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*. 2013.
67. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell*. 2010;38(4):576-89.
68. Mclean CY, Bristor D, Hiller M, Clarke SL, Schafer BT, Lowe CB, et al. Analysis GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol*. 2010;28(5):491-501.
69. Chèneby J, Artufel M, Ballester B, Gheorghe M, Mathelier A. ReMap 2018: an updated atlas of regulatory regions from an integrative analysis of DNA-binding ChIP-seq experiments. *Nucleic Acids Res*. 2017;46(D1):D267-D275.
70. Ramírez F, Bhardwaj V, Arrigoni L, Lam KC, Grüning BA, Villaveces J, et al. High-resolution TADs reveal sequences.
71. Li H, Durbin R. Fast and accurate short read alignment with Burrows – Wheeler transform. *Bioinformatics*. 2009;25.
72. Chu T, Rice EJ, Booth GT, Salamanca HH, Wang Z, Core LJ, et al. Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme. *Nat Genet*. 2018;50(11).
73. Gertz J, Savic D, Varley KE, Partridge EC, Safi A, Jain P, et al. Distinct properties of cell-type-specific and shared transcription factor binding sites. *Mol Cell*. 2013;52.
74. Rao SSP, Huang S-C, Glenn St Hilaire B, Engreitz JM, Perez EM, Kieffer-Kwon KR, et al. Cohesin loss eliminates all loop domains. *Cell*. 2017;171.
75. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013;8(11).

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

